# A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

> **NCT07422753** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 36 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** placebo
- **DRUG:** CTLA-4 Antibody(ipilimumab N01)

## Key facts

- **NCT ID:** NCT07422753
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-25
- **Primary completion:** 2027-03
- **Final completion:** 2029-03
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07422753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07422753, "A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07422753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*